RE:RE:RE:TLD1433 versus the FluRumpl3StiltSkin wrote: TLT's tech does too much, has too much interest, to remain priced where it is much longer. Someone is going to want this tech in their portfolio. I'm expecting a buyout within the next year.
What do you think Slayer?
CancerSlayer wrote: Great find Eoganacht & thanks for sharing...
Dr. Coombs' lab has produced a lot of exciting findings over the years...the fact that the TLD-1433/PDT technology was chosen for this competition illustrates not only Dr. Coombs' confidence in his findings, but also highlights the clinical potential of this technology as both an antiviral treatment & preventative vaccine...not to mention its potential clinical activity against many other RNA enveloped viruses, including Zeka & Coronaviruses. Will be watching...
This is purely opinion, but my thought is Big Pharma is already wrapping its tentacles around our promising tech. Big news in the quarterly (& I believe cashascars assumption has merit) will simply add to this belief. My supposition only, but Big Pharma interest & influence could also explain the recent mysterious/apparent disconnect that occurred with Roswell. As we all know, this tech has the potential to capture a hugely profitable portion of the market. It stands to reason that an interested suitor would want to monopolize & keep a lid on such tech. Any potential suitor would have little incentive to support close ties with a Roswell/Lumeda arrangement that could cut into future market control & big profits. I think Big Pharma pursues such ties primarily when the targeted technology is still in need of significantly more (& more expensive) R & D and/or when sales are anticipated to be significantly less meaningful. I don't believe the current perception of our tech's potential falls into the latter category. All JMHO.